RNA Chemical Tag Emerges as Hidden Driver of Kidney Damage in Diabetes

Deep inside the filters of the kidney, a microscopic cellular drama unfolds every day in people living with diabetes. Now, a team of nephrology researchers in China has traced that drama down to its molecular roots, uncovering a chain of events that begins with a chemical tag on a strand of RNA and ends with the destruction of the cells that keep the kidney’s blood-filtering apparatus intact. The study, published in Cellular and Molecular Life Sciences, identifies a signaling pathway that could become a fresh target for treating diabetic kidney disease, the leading cause of end-stage kidney failure worldwide.

The cells at the center of the story are podocytes, highly specialized epithelial cells that wrap around the tiny capillary loops of the glomerulus, the kidney’s filtration unit. Podocytes extend intricate foot processes that interlock to form slits through which blood is filtered, and their integrity is essential for keeping protein from leaking into the urine. When podocytes are injured or lost, the filtration barrier breaks down, proteinuria develops, and progressive scarring follows. Podocyte injury is widely regarded as a decisive event in diabetic kidney disease, which is why understanding exactly how high blood sugar damages these cells has become one of the most pressing questions in nephrology.

The new research focuses on an unexpected player: FTO, the fat-mass and obesity-associated protein. FTO first rose to fame through genome-wide association studies linking variants in its gene to human obesity, but it was later shown to be an enzyme that removes a specific chemical modification from RNA molecules. That modification, N6-methyladenosine, or m6A, is the most abundant internal mark on messenger RNA in higher organisms. By adding or erasing m6A, cells can fine-tune how long a given mRNA survives, how efficiently it is translated into protein, and how it is processed. In earlier work, the team had manipulated FTO in podocytes and performed parallel methylated RNA immunoprecipitation sequencing and RNA sequencing, a combination that reveals both which transcripts carry m6A marks and how overall gene expression changes. That screen pointed them toward early growth response 1, or EGR1, a transcription factor whose precise role in diabetic kidney disease had remained unclear.

The findings that followed connect the dots in a strikingly mechanistic way. The researchers demonstrated that FTO is critical to podocyte injury because it enhances the stability of EGR1 mRNA in a manner dependent on m6A and on YTHDF2, a reader protein that binds methylated RNA and directs its fate. In other words, by removing methyl marks from the EGR1 transcript, FTO protects that message from YTHDF2-mediated degradation, allowing more EGR1 protein to be produced. The team also found that EGR1 is elevated in podocytes taken from people with diabetic kidney disease, and that its levels correlate with estimated glomerular filtration rate and with 24-hour urinary protein, two clinical measures of how well the kidney is functioning and how badly the filter is leaking.

Experiments in cultured human podocytes reinforced the picture. When the cells were exposed to high glucose, mimicking the diabetic environment, EGR1 expression climbed. Silencing EGR1 eased both the injury and the inflammation that high glucose provokes in podocytes, while forcing the cells to overproduce EGR1 made the damage worse. This dose-and-direction relationship, in which turning the gene down protects and turning it up harms, is exactly what one would expect from a genuine driver of the disease process rather than a passive bystander.

The mechanistic core of the study lies in what EGR1 does once it is produced. Using chromatin immunoprecipitation, the researchers showed that EGR1 binds directly to the promoter of STING1, the gene encoding stimulator of interferon genes 1, a protein better known as a central hub of innate immune signaling. By occupying its promoter, EGR1 boosts STING1 transcription, which in turn activates the STING1/TBK1/NF-κB signaling cascade. This cascade is a classic inflammatory pathway: STING1 activates TBK1, a kinase that then activates NF-κB, a transcription factor that switches on a battery of inflammatory genes. The result is a self-reinforcing inflammatory attack on the podocyte from within, driven ultimately by an RNA modification laid down by FTO.

To test whether the pathway matters in a living organism, the team turned to mouse models of diabetes induced by streptozotocin and a high-fat diet, which together reproduce key features of the human disease. Using adeno-associated virus vectors to deliver genetic constructs specifically to podocytes, they deleted or upregulated EGR1 in these cells. The outcome was unambiguous. Podocyte-specific deletion of EGR1 significantly reduced podocyte and glomerular damage in the diabetic mice, preserving the structure of the filtration barrier. Conversely, when EGR1 was deliberately elevated in podocytes, the mice suffered worse podocyte injury and heavier proteinuria. The same gene that protected cells when removed caused harm when amplified, confirming EGR1 as a pivotal node in the disease cascade in vivo.

The study is notable for the way it stitches together three layers of biology that are usually studied separately: epitranscriptomics, the chemistry of RNA modifications; transcriptional regulation, the control of gene expression by DNA-binding factors; and innate immunity, the inflammatory machinery that cells deploy against perceived threats. In the podocytes of a diabetic kidney, these layers converge into a single pathway. High glucose and FTO activity conspire to stabilize EGR1 mRNA, EGR1 protein then switches on STING1, and the STING1/TBK1/NF-κB axis ignites inflammation that erodes the kidney’s filter. Each link in that chain is a potential point of intervention, and the authors suggest that EGR1 itself could be a prospective new treatment strategy for diabetic kidney disease.

The clinical stakes are considerable. Current therapy for diabetic kidney disease rests on controlling blood glucose and blood pressure and on blocking the renin-angiotensin system with drugs such as angiotensin-converting enzyme inhibitors, alongside newer agents including SGLT2 inhibitors. Yet a large fraction of patients still progress toward dialysis or transplant, so molecular targets that address the injury process itself, rather than its systemic drivers, are eagerly sought. Because EGR1 sits downstream of FTO and upstream of the inflammatory cascade, drugging it or its partners might blunt podocyte inflammation even when metabolic control is imperfect. Any such approach would need to reckon with the fact that EGR1 is an immediate-early transcription factor with many roles in other tissues, so specificity will be a central challenge for future drug development.

There are also caveats that temper the excitement. The human evidence consists of correlations between EGR1 levels in podocytes and clinical markers, which, while consistent with the mechanistic data, cannot by themselves prove causation in patients. The mouse model, though well established, does not capture every feature of human diabetic nephropathy, and the viral vectors used to manipulate EGR1 in podocytes are research tools rather than therapeutic vehicles. The published version of the study is open access, allowing clinicians and researchers worldwide to scrutinize the data, and the work was approved by the relevant ethics committees at Shandong Provincial Hospital with informed consent from all participants. Even so, the study offers something the field has lacked: a complete, testable narrative linking an RNA demethylase, a methylated mRNA, an immune signaling hub, and the slow-motion catastrophe of the diabetic glomerulus. If that narrative holds up in further studies, the humble chemical tag on a strand of RNA may turn out to be one of diabetes’ most consequential accomplices, and shutting down its effects could help millions of people keep their kidneys working longer.

Subject of Research: FTO-mediated m6A modification of EGR1 mRNA and its role in podocyte injury and inflammation in diabetic kidney disease

Article Title: FTO-mediated m6A modification of EGR1 mRNA promotes podocyte injury and inflammation via STING1 in diabetic kidney disease

Article References: Hu, J., Liu, Y., Lang, Y., Liu, B., Fan, X., Yang, M., Shen, N., Zhang, D., Zhang, X., Chai, S., Zeng, Z., Shang, J., Wang, R., & Lv, Z. (2026). FTO-mediated m6A modification of EGR1 mRNA promotes podocyte injury and inflammation via STING1 in diabetic kidney disease. Cellular and Molecular Life Sciences. https://doi.org/10.1007/s00018-026-06474-w

Image Credits: AI Generated

DOI: 10.1007/s00018-026-06474-w

Keywords: diabetic kidney disease, podocytes, FTO, EGR1, STING1, m6A modification, RNA demethylase, YTHDF2, NF-kappaB, inflammation, proteinuria, nephrology